Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 1.86B -43.2% |
| Revenue (ttm) | n/a |
| Net Income | -349.58M |
| EPS | -4.38 |
| Shares Out | 88.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,346,442 |
| Open | 22.04 |
| Previous Close | 22.23 |
| Day's Range | 20.41 - 22.82 |
| 52-Week Range | 20.41 - 47.65 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 46.33 (+120.62%) |
| Est. Earnings | Nov 9, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $46.33, which is an increase of 120.62% from the latest price.
News
Mineralys Therapeutics initiated with a Neutral at UBS
UBS initiated coverage of Mineralys Therapeutics (MLYS) with a Neutral rating and $29 price target The company’s lorundrostat, an aldosterone synthase inhibitor for later-line hypertension, is positio...
Mineralys Therapeutics presents new analysis from Launch-HTN trial
Mineralys Therapeutics (MLYS) announced the presentation of a new analysis from its pivotal Phase 3 Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA...
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressur...
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Aldosterone synthase inhibitors are reshaping hypertension treatment, with lorundrostat poised for launch following robust phase III data and strong payer interest. Commercial plans target both specialist and primary care channels, with initial access in fourth-line therapy and expansion expected.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Lorundrostat is advancing toward a December PDUFA date, supported by robust clinical data and a comprehensive commercial build-out targeting third- and fourth-line hypertension. The launch strategy emphasizes parity access, broad prescriber reach, and ongoing R&D, with full funding secured through 2028.
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics reports Q2 EPS ($2.85), consensus (54c)
Research and development expenses for the quarter ended June 30 were $221.4M, compared to $38.3M for the quarter ended June 30, 2025. The increase in R&D expenses was primarily due…
Mineralys Therapeutics price target lowered to $49 from $51 at BofA
BofA lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $49 from $51 and keeps a Buy rating on the shares. The firm’s lower target is driven by lowering…
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major investments in launch readiness, clinical progress, and capital structure, with lorundrostat positioned for a December PDUFA. Strong cash reserves support operations into 2028, while payer and market feedback remain positive for commercial success.
Mineralys Therapeutics Earnings release: Q2 2026
Mineralys Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Mineralys Therapeutics Quarterly report: Q2 2026
Mineralys Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as C...
Mineralys Therapeutics Slides: Corporate presentation
Mineralys Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Mineralys Therapeutics presents late-breaking data on lorundrostat
Mineralys Therapeutics (MLYS) presented new data on the effect of lorundrostat on heart failure risk biomarkers. This post hoc analysis of circulating proteomic data from participants enrolled in the ...
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
Mineralys Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lorundrostat’s NDA is under FDA review with a December PDUFA date, and preparations for launch are well underway, including a strategic royalty buyback and new financing. Recent clinical data support efficacy and safety in both CKD and non-CKD patients, and market access is expected to begin in fourth-line hypertension with rapid expansion.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment Late-breaking presentation reports a proteomic analysis of heart failure biomarkers du...
Mineralys Therapeutics falls -17.1%
Mineralys Therapeutics (MLYS) is down -17.1%, or -$4.93 to $23.92.